Key result
Chronic alveolar hypoxia attenuates adverse LV remodeling and heart failure in pressure-overload mice.
Why the study?
Alveolar hypoxia is protective in cardiovascular disease, but underlying mechanisms are incompletely understood, prompting investigation into whether hypoxia protects against LVPO-induced heart failure and shares mechanisms with post-LVAD cardiac recovery.
Does chronic alveolar hypoxia attenuate pressure overload-induced heart failure in a murine model?
Does chronic alveolar hypoxia attenuate pressure overload-induced heart failure in a murine model?
Mild alveolar hypoxia attenuates pressure overload-induced heart failure in mice via angiogenesis and metabolic preservation, revealing potential therapeutic targets like Tbx5 and HSD11B1 for myocardial recovery.
Answers are grounded in this paper and cite their sources.
Supports hypoxia-related pathways in murine TAC; leaves open translation to human pressure-overload HF.
Background Alveolar hypoxia is protective in the context of cardiovascular and ischemic heart disease; however, the underlying mechanisms are incompletely understood. The present study sought to test the hypothesis that hypoxia is cardioprotective in left ventricular pressure overload (LVPO)–induced heart failure. We furthermore aimed to test that overlapping mechanisms promote cardiac recovery in heart failure patients following left ventricular assist device‐mediated mechanical unloading and circulatory support. Methods and Results We established a novel murine model of combined chronic alveolar hypoxia and LVPO following transverse aortic constriction (HxTAC). The HxTAC model is resistant to cardiac hypertrophy and the development of heart failure. The cardioprotective mechanisms identified in our HxTAC model include increased activation of HIF (hypoxia‐inducible factor)‐1α–mediated angiogenesis, attenuated induction of genes associated with pathological remodeling, and preserved metabolic gene expression as identified by RNA sequencing. Furthermore, LVPO decreased Tbx5 and increased Hsd11b1 mRNA expression under normoxic conditions, which was attenuated under hypoxic conditions and may induce additional hypoxia‐mediated cardioprotective effects. Analysis of samples from patients with advanced heart failure that demonstrated left ventricular assist device–mediated myocardial recovery revealed a similar expression pattern for TBX5 and HSD11B1 as observed in HxTAC hearts. Conclusions Hypoxia attenuates LVPO‐induced heart failure. Cardioprotective pathways identified in the HxTAC model might also contribute to cardiac recovery following left ventricular assist device support. These data highlight the potential of our novel HxTAC model to identify hypoxia‐mediated cardioprotective mechanisms and therapeutic targets that attenuate LVPO‐induced heart failure and mediate cardiac recovery following mechanical circulatory support.
No takes yet. Share an insight, caveat, or question.
Froese et al. (2024) studied Left ventricular pressure overload-induced heart failure. Chronic alveolar hypoxia vs. Normoxia (21% oxygen in room air) was evaluated on Left ventricular contractile function, cardiac hypertrophy, and adverse remodeling. Chronic alveolar hypoxia attenuated adverse left ventricular remodeling, contractile dysfunction, and the development of heart failure following transverse aortic constriction in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: